Literature DB >> 33150361

Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy.

Keith A Josephs1, Peter R Martin2, Stephen D Weigand2, Nirubol Tosakulwong2, Marina Buciuc1, Melissa E Murray3, Leonard Petrucelli4, Matthew L Senjem5,6, Anthony J Spychalla5,6, David S Knopman1, Bradley F Boeve1, Ronald C Petersen1, Joseph E Parisi7, Dennis W Dickson3, Clifford R Jack5, Jennifer L Whitwell5.   

Abstract

Alzheimer's disease is characterized by the presence of amyloid-β and tau deposition in the brain, hippocampal atrophy and increased rates of hippocampal atrophy over time. Another protein, TAR DNA binding protein 43 (TDP-43) has been identified in up to 75% of cases of Alzheimer's disease. TDP-43, tau and amyloid-β have all been linked to hippocampal atrophy. TDP-43 and tau have also been linked to hippocampal atrophy in cases of primary age-related tauopathy, a pathological entity with features that strongly overlap with those of Alzheimer's disease. At present, it is unclear whether and how TDP-43 and tau are associated with early or late hippocampal atrophy in Alzheimer's disease and primary age-related tauopathy, whether either protein is also associated with faster rates of atrophy of other brain regions and whether there is evidence for protein-associated acceleration/deceleration of atrophy rates. We therefore aimed to model how these proteins, particularly TDP-43, influence non-linear trajectories of hippocampal and neocortical atrophy in Alzheimer's disease and primary age-related tauopathy. In this longitudinal retrospective study, 557 autopsied cases with Alzheimer's disease neuropathological changes with 1638 ante-mortem volumetric head MRI scans spanning 1.0-16.8 years of disease duration prior to death were analysed. TDP-43 and Braak neurofibrillary tangle pathological staging schemes were constructed, and hippocampal and neocortical (inferior temporal and middle frontal) brain volumes determined using longitudinal FreeSurfer. Bayesian bivariate-outcome hierarchical models were utilized to estimate associations between proteins and volume, early rate of atrophy and acceleration in atrophy rates across brain regions. High TDP-43 stage was associated with smaller cross-sectional brain volumes, faster rates of brain atrophy and acceleration of atrophy rates, more than a decade prior to death, with deceleration occurring closer to death. Stronger associations were observed with hippocampus compared to temporal and frontal neocortex. Conversely, low TDP-43 stage was associated with slower early rates but later acceleration. This later acceleration was associated with high Braak neurofibrillary tangle stage. Somewhat similar, but less striking, findings were observed between TDP-43 and neocortical rates. Braak stage appeared to have stronger associations with neocortex compared to TDP-43. The association between TDP-43 and brain atrophy occurred slightly later in time (∼3 years) in cases of primary age-related tauopathy compared to Alzheimer's disease. The results suggest that TDP-43 and tau have different contributions to acceleration and deceleration of brain atrophy rates over time in both Alzheimer's disease and primary age-related tauopathy.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Braak stage; PART; TDP-43; longitudinal; rate of atrophy

Mesh:

Substances:

Year:  2020        PMID: 33150361      PMCID: PMC7719030          DOI: 10.1093/brain/awaa299

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  60 in total

1.  Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.

Authors:  Shinji Higashi; Eizo Iseki; Ryoko Yamamoto; Michiko Minegishi; Hiroaki Hino; Koshiro Fujisawa; Takashi Togo; Omi Katsuse; Hirotake Uchikado; Yoshiko Furukawa; Kenji Kosaka; Heii Arai
Journal:  Brain Res       Date:  2007-10-25       Impact factor: 3.252

2.  Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.

Authors:  Eric McDade; Guoqiao Wang; Brian A Gordon; Jason Hassenstab; Tammie L S Benzinger; Virginia Buckles; Anne M Fagan; David M Holtzman; Nigel J Cairns; Alison M Goate; Daniel S Marcus; John C Morris; Katrina Paumier; Chengjie Xiong; Ricardo Allegri; Sarah B Berman; William Klunk; James Noble; John Ringman; Bernardino Ghetti; Martin Farlow; Reisa A Sperling; Jasmeer Chhatwal; Stephen Salloway; Neill R Graff-Radford; Peter R Schofield; Colin Masters; Martin N Rossor; Nick C Fox; Johannes Levin; Mathias Jucker; Randall J Bateman
Journal:  Neurology       Date:  2018-09-14       Impact factor: 9.910

3.  Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.

Authors:  B T Hyman; J Q Trojanowski
Journal:  J Neuropathol Exp Neurol       Date:  1997-10       Impact factor: 3.685

4.  Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART).

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Jennifer L Whitwell; David S Knopman; Mary M Machulda; Stephen D Weigand; Bradley F Boeve; Kejal Kantarci; Leonard Petrucelli; Val J Lowe; Clifford R Jack; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2017-02-03       Impact factor: 17.088

5.  PART, a distinct tauopathy, different from classical sporadic Alzheimer disease.

Authors:  Kurt A Jellinger; Irina Alafuzoff; Johannes Attems; Thomas G Beach; Nigel J Cairns; John F Crary; Dennis W Dickson; Patrick R Hof; Bradley T Hyman; Clifford R Jack; Gregory A Jicha; David S Knopman; Gabor G Kovacs; Ian R Mackenzie; Eliezer Masliah; Thomas J Montine; Peter T Nelson; Frederick Schmitt; Julie A Schneider; Albert Serrano-Pozo; Dietmar R Thal; Jonathan B Toledo; John Q Trojanowski; Juan C Troncoso; Jean Paul Vonsattel; Thomas Wisniewski
Journal:  Acta Neuropathol       Date:  2015-03-17       Impact factor: 17.088

6.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

7.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

8.  3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease.

Authors:  Jennifer L Whitwell; Scott A Przybelski; Stephen D Weigand; David S Knopman; Bradley F Boeve; Ronald C Petersen; Clifford R Jack
Journal:  Brain       Date:  2007-05-28       Impact factor: 13.501

9.  Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration.

Authors:  Kelvin K Leung; Jonathan W Bartlett; Josephine Barnes; Emily N Manning; Sebastien Ourselin; Nick C Fox
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

10.  Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.

Authors:  Brian A Gordon; Tyler M Blazey; Yi Su; Amrita Hari-Raj; Aylin Dincer; Shaney Flores; Jon Christensen; Eric McDade; Guoqiao Wang; Chengjie Xiong; Nigel J Cairns; Jason Hassenstab; Daniel S Marcus; Anne M Fagan; Clifford R Jack; Russ C Hornbeck; Katrina L Paumier; Beau M Ances; Sarah B Berman; Adam M Brickman; David M Cash; Jasmeer P Chhatwal; Stephen Correia; Stefan Förster; Nick C Fox; Neill R Graff-Radford; Christian la Fougère; Johannes Levin; Colin L Masters; Martin N Rossor; Stephen Salloway; Andrew J Saykin; Peter R Schofield; Paul M Thompson; Michael M Weiner; David M Holtzman; Marcus E Raichle; John C Morris; Randall J Bateman; Tammie L S Benzinger
Journal:  Lancet Neurol       Date:  2018-02-01       Impact factor: 44.182

View more
  13 in total

1.  Differences in Symptomatic Presentation and Cognitive Performance Among Participants With LATE-NC Compared to FTLD-TDP.

Authors:  Merilee A Teylan; Charles Mock; Kathryn Gauthreaux; Jessica E Culhane; Gregory Jicha; Yen-Chi Chen; Kwun C G Chan; Walter A Kukull; Peter T Nelson; Yuriko Katsumata
Journal:  J Neuropathol Exp Neurol       Date:  2021-10-01       Impact factor: 3.685

2.  TDP-43 Pathology Exacerbates Cognitive Decline in Primary Age-Related Tauopathy.

Authors:  Denis S Smirnov; David P Salmon; Douglas Galasko; Steven D Edland; Donald P Pizzo; Vanessa Goodwill; Annie Hiniker
Journal:  Ann Neurol       Date:  2022-07-11       Impact factor: 11.274

Review 3.  Emotion Processing Dysfunction in Alzheimer's Disease: An Overview of Behavioral Findings, Systems Neural Correlates, and Underlying Neural Biology.

Authors:  Shefali Chaudhary; Simon Zhornitsky; Herta H Chao; Christopher H van Dyck; Chiang-Shan R Li
Journal:  Am J Alzheimers Dis Other Demen       Date:  2022 Jan-Dec       Impact factor: 2.632

4.  Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.

Authors:  Keith A Josephs; Stephen D Weigand; Jennifer L Whitwell
Journal:  Neurology       Date:  2022-03-21       Impact factor: 11.800

5.  Old age genetically confirmed frontotemporal lobar degeneration with TDP-43 has limbic predominant TDP-43 deposition.

Authors:  Marina Buciuc; Jennifer L Whitwell; Matthew C Baker; Rosa Rademakers; Dennis W Dickson; Keith A Josephs
Journal:  Neuropathol Appl Neurobiol       Date:  2021-05-21       Impact factor: 8.090

6.  Multi-Resemblance Multi-Target Low-Rank Coding for Prediction of Cognitive Decline With Longitudinal Brain Images.

Authors:  Jie Zhang; Jianfeng Wu; Qingyang Li; Richard J Caselli; Paul M Thompson; Jieping Ye; Yalin Wang
Journal:  IEEE Trans Med Imaging       Date:  2021-07-30       Impact factor: 11.037

Review 7.  Pathway from TDP-43-Related Pathology to Neuronal Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.

Authors:  Yuichi Riku; Danielle Seilhean; Charles Duyckaerts; Susana Boluda; Yohei Iguchi; Shinsuke Ishigaki; Yasushi Iwasaki; Mari Yoshida; Gen Sobue; Masahisa Katsuno
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

8.  TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death.

Authors:  Marina Buciuc; Nirubol Tosakulwong; Mary M Machulda; Jennifer L Whitwell; Stephen D Weigand; Melissa E Murray; R Ross Reichard; Joseph E Parisi; Dennis W Dickson; Bradley F Boeve; David S Knopman; Ronald C Petersen; Keith A Josephs
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

9.  Mesial temporal tau in amyloid-β-negative cognitively normal older persons.

Authors:  Natasha Krishnadas; Vincent Doré; Colin Groot; Fiona Lamb; Pierrick Bourgeat; Samantha C Burnham; Kun Huang; Anita M Y Goh; Colin L Masters; Victor L Villemagne; Christopher C Rowe
Journal:  Alzheimers Res Ther       Date:  2022-04-08       Impact factor: 8.823

10.  White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition.

Authors:  Sheelakumari Raghavan; Scott A Przybelski; Robert I Reid; Timothy G Lesnick; Vijay K Ramanan; Hugo Botha; Billie J Matchett; Melissa E Murray; R Ross Reichard; David S Knopman; Jonathan Graff-Radford; David T Jones; Val J Lowe; Michelle M Mielke; Mary M Machulda; Ronald C Petersen; Kejal Kantarci; Jennifer L Whitwell; Keith A Josephs; Clifford R Jack; Prashanthi Vemuri
Journal:  Acta Neuropathol Commun       Date:  2022-02-05       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.